News and Press Releases
IBSA UK&I assumes direct commercial responsibility for ialuril in the UK and Ireland
Transition supports continuity of supply and aligns ialuril with IBSA’s expanding UK uro-gynaecology portfolio 9 April 2026 -- Watford, UK -- IBSA UK&I, the UK subsidiary of Swiss pharmaceutical company...
Category: BioManufacturing, Other, Pharmaceutical
Posted: April 9, 2026
Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California
24 February 2026 -- California, US -- Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand opening of its new Early Phase Center of Excellence, a state of...
Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: February 24, 2026
Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer
Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a...
Category: Drug Delivery, Other, Pharmaceutical
Posted: November 25, 2025
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
21 May 2025 -- Surrey, UK -- Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final draft guidance which recommends Hympavzi (marstacimab)...
Category: Drug Discovery, Other, Pharmaceutical
Posted: May 21, 2025
Carbon Minimal pressurised Metered Dose Inhalers (pMDIs) could save up to 619,000 tonnes of emissions each year, representing up to 7%-10% of NHS Net Zero targets
At a national level, seamless transitioning to a range of carbon minimal pMDIs could save between 415,000 and 619,000 tCO₂e annually, reducing carbon emissions to the equivalent financial value of...
Category: Drug Delivery, Manufacturing and Packing
Posted: March 10, 2025
NHS patients receive medicines manufactured by Octapharma using UK-donated plasma for the first time in almost 30 years
The sole manufacturer for the UK’s Plasma for Medicines (PfM) programme is supporting the Department of Health and Social Care, NHS England, and NHS Blood and Transplant to build resilience...
Category: Other, Pharmaceutical
Posted: March 6, 2025
Medicines manufacturing skills project uses Virtual Reality to help NHS reach net zero
Resilience, a UK government initiative, says its use of VR will reduce travel and waste 10 February 2025 – The recently launched government-funded medicines manufacturing skills project, Resilience, has said...
Category: Manufacturing and Packing
Posted: February 11, 2025
AbbVie’s SKYRIZI® (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis
Risankizumab will be available on the NHS in Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to,...
Category: Clinical Trials, Pharmaceutical
Posted: January 13, 2025
Major distribution centre opens to support health services in North West England
18 July 2024 – Nottingham, UK – A new NHS Supply Chain regional distribution centre that will support 115 NHS Trusts is now fully operational, providing a more resilient and...
Category: Logistics, Manufacturing and Packing
Posted: July 31, 2024
GSK’s Jemperli▼ (dostarlimab) is accepted for use within NHS Scotland, in line with its licence, in eligible endometrial cancer patients in first line setting
Clinicians in Scotland will now be able to use dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced...
Category: Pharmaceutical
Posted: April 8, 2024
Scottish Medicines Consortium (SMC) accepts Camzyos▼(mavacamten) for use on the NHS as an adjunct treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy
Mavacamten has been accepted for use within NHS Scotland for the treatment of symptomatic(New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy(HCM) in adult patients. HCM is...
Category: Pharmaceutical
Posted: April 8, 2024
ARC Uxbridge Sanderson Road New Denham Denham Buckinghamshire UB8 1DH
